Table 2. Mean all grades of each side effect linked to cardiotoxicity of the BRAF inhibitors.
| Drug | Side effect (mean all grades) | ||||
|---|---|---|---|---|---|
| Hypertension | Cardiac ischemia / Infarction | Arterial thrombo-embolic events | QT prolongation / ECG changes | CHF and/or symptoms related (e.g. Asthenia, Dyspnea, Peripheral edema) | |
| Sorafenib | ~ 22.6 % | ~ 2.5 % | ~ 1.7 % | ~ 8.1 % | ~ 14.5 % |
| Vemurafenib | 6 % | ------ | ------ | ~ 8.5 % | ~ 8.8 % |
| Regorafenib | ~ 37.5 % | ~ 1.2 % | ~ 2 % | No clinically significant effect | 6 % |
| Dabrafenib | ------ | ------ | ------ | ------ | ------ |